Oppenheimer Reaffirms “Buy” Rating for Cryolife (NYSE:CRY)

Oppenheimer restated their buy rating on shares of Cryolife (NYSE:CRY) in a research note released on Thursday, TipRanks reports. The brokerage currently has a $25.00 target price on the medical equipment provider’s stock.

Other research analysts have also recently issued reports about the stock. Needham & Company LLC assumed coverage on shares of Cryolife in a report on Tuesday, June 30th. They issued a buy rating and a $29.00 target price for the company. Zacks Investment Research cut shares of Cryolife from a buy rating to a hold rating in a report on Thursday, July 2nd. TheStreet cut shares of Cryolife from a c- rating to a d+ rating in a report on Friday, July 10th. Finally, Lake Street Capital increased their target price on shares of Cryolife from $22.00 to $27.00 and gave the company a buy rating in a report on Friday, May 1st. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Cryolife currently has an average rating of Buy and an average price target of $26.20.

NYSE CRY opened at $19.41 on Thursday. The stock has a market capitalization of $732.53 million, a P/E ratio of 323.50 and a beta of 1.37. Cryolife has a 52-week low of $12.63 and a 52-week high of $33.00. The firm has a 50-day moving average price of $19.57 and a 200 day moving average price of $22.63. The company has a quick ratio of 3.66, a current ratio of 4.90 and a debt-to-equity ratio of 0.94.

Cryolife (NYSE:CRY) last posted its quarterly earnings results on Thursday, July 30th. The medical equipment provider reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.01. Cryolife had a negative net margin of 4.33% and a positive return on equity of 0.98%. The firm had revenue of $53.77 million during the quarter, compared to analysts’ expectations of $51.30 million. On average, equities research analysts expect that Cryolife will post -0.17 earnings per share for the current fiscal year.

In other news, Director Ronald D. Mccall sold 1,719 shares of the stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $22.82, for a total value of $39,227.58. Following the sale, the director now directly owns 127,766 shares in the company, valued at $2,915,620.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.70% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC acquired a new stake in shares of Cryolife in the first quarter valued at approximately $27,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Cryolife by 37.8% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,093 shares of the medical equipment provider’s stock worth $52,000 after acquiring an additional 848 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in Cryolife by 272.0% during the first quarter. PNC Financial Services Group Inc. now owns 4,564 shares of the medical equipment provider’s stock worth $76,000 after acquiring an additional 3,337 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Cryolife by 36.5% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,223 shares of the medical equipment provider’s stock worth $81,000 after acquiring an additional 1,130 shares during the last quarter. Finally, Exchange Traded Concepts LLC boosted its position in Cryolife by 67.8% during the first quarter. Exchange Traded Concepts LLC now owns 5,375 shares of the medical equipment provider’s stock worth $91,000 after acquiring an additional 2,171 shares during the last quarter. Institutional investors and hedge funds own 81.91% of the company’s stock.

About Cryolife

CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.

Read More: Initial Coin Offering (ICO)

Analyst Recommendations for Cryolife (NYSE:CRY)

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.